|
|
Profile
|
Delegates :
KIYOSHI TAKAYAMA |
|
Incorporated :
July 7 , 2006 |
Paid in Capital :
263 Million yen |
Employees :
23 人 |
Address :
North 21 West 12, Kita-Ku, Sapporo HOKKAIDO
〒001-0021
|
TEL/FAX :
+81-11-708-7156 / +81-11-708-7157 |
URL：
https://nbhl.co.jp/ |
Attachment :
|
Mission/Background :
Philosophy
-Vision
Our vision is to be an R&D-driven, global biotechnology company that continuously creates new medicines.
-Missioin
We contribute to people's health and local economies by developing new drug pipelines and bringing innovative products to the world.
Business Model
Hybrid Drug Discovery Business Model with MoGRAA(R) Discovery Engine + Attractive GPCR-targeted antibody pipelines |
|
Technology & Business
|
Technology
The MoGRAA(R) Discovery Engine is a drug discovery platform developed by our company for obtaining GPCR-targeting antibodies.
The MoGRAA(R) Discovery Engine makes it possible to efficiently obtain monoclonal antibodies that specifically bind to target GPCRs.
Business Overview
Since our inception, we have focused on functional monoclonal antibodies targeting G protein-coupled receptors (GPCRs) to break new ground in GPCR drug discovery.
We have the cutting-edge "MoGRAA&(R) Discovery Engine" technology for developing therapeutic functional antibodies against GPCRs as our core technology, and we aim to contribute to human health by pioneering new fields in drug discovery targeting GPCRs.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Technology Platform for Functional Therapeutic GPCR mAbs
|
Discovery
|
Technology Platform fit the development of functional GPCR mAbs with the proprietary technolo
|
Conclusion of on-going partnership agreements
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
Achievements
We have discovered new antibody drug seeds targeting GPCRs and are working with multiple universities and companies to advance preclinical development.
|
|
Alliance strategy
|
NBHL is proud to introduce our promising pipelines to pharmaceutical companies. We are seeking partners particularly for the clinical development and commercialization of the following diseases and pipelines.
・Focus therapeutic areas: fibrosis, autoimmune diseases, severe viral infections
・Pipelines: please see our website
We are looking for pharmaceutical companies and biotech companies globally, which have interest in using "MoGRAA(R) Discovery Engine".
|
|
|